Effects of the anti-receptor activator of nuclear factor kappa B ligand denusomab on beta thalassemia major-induced osteoporosis.

Introduction: Osteoporosis represents the second most common cause of endocrinopathy in patients with beta thalassemia major (BTM). Some drugs proved effective to reduce vertebral and non-vertebral fracture risk. Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor kappa B ligand (RANKL), a member of the tumor necrosis factor receptor superfamily essential for osteoclastogenesis.

Prevalence of undernutrition in a long-term care facility in Qatar.

This study assessed the nutritional status of 130 Qatari patients aged 65 to 90 years who were residing in a long-term care facility for six months. Admission weight was not measured for 49.2% of the subjects.